Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD

Marc Miravitlles, Ariadna Auladell-Rispau, Mònica Monteagudo, Juan Carlos Vázquez-Niebla, Jibril Mohammed, Alexa Nuñez, Gerard Urrútia
European Respiratory Review 2021 30: 210075; DOI: 10.1183/16000617.0075-2021
Marc Miravitlles
1Pneumology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
6Both authors contributed equally and are considered first authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Miravitlles
  • For correspondence: marcm@separ.es
Ariadna Auladell-Rispau
2Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
6Both authors contributed equally and are considered first authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mònica Monteagudo
3Primary Care University Research Institute Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain
4Medicine Dept, Universitat Autònoma de Barcelona (UAB), Bellaterra (Cerdanyola del Vallès), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Carlos Vázquez-Niebla
2Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jibril Mohammed
5Dept of Physiotherapy, Bayero University, Kano, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexa Nuñez
1Pneumology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard Urrútia
2Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Inhaled corticosteroids (ICSs) are indicated for the prevention of exacerbations in COPD; however, a significant proportion of patients at low risk of exacerbations are treated with ICSs. We conducted a systematic review including a diversity of types of study designs and safety outcomes with the objective of describing the risk of adverse effects associated with the long-term use of ICSs in patients with COPD.

A total of 90 references corresponding to 83 studies were included, including 26 randomised clinical trials (RCTs), 33 cohort studies, and 24 nested case–control (NCC) studies. Analysis of 19 RCTs showed that exposure to ICSs for ≥1 year increased the risk of pneumonia by 41% (risk ratio 1.41, 95% CI 1.23–1.61). Additionally, cohort and NCC studies showed an association between ICSs and risk of tuberculosis and mycobacterial disease. There was a strong association between ICS use and local disorders such as oral candidiasis and dysphonia. The association between ICSs and the risk of diabetes and fractures was less clear and appeared significant only at high doses of ICSs.

Since most patients with COPD are elderly and with frequent comorbidities, an adequate risk–benefit balance is crucial for the indication of ICSs.

Abstract

Long-term use of inhaled corticosteroids in COPD is associated with a significantly increased risk of side-effects, especially oral candidiasis, dysphonia, pneumonia, mycobacterial disease, diabetes and fractures https://bit.ly/3t0AGfO

Introduction

Inhaled corticosteroids (ICSs) combined with long-acting bronchodilators are indicated for patients with COPD who experience exacerbations despite treatment with long-acting β2-agonists (LABAs) and long-acting antimuscarinic agents (LAMAs) [1]. Furthermore, recent studies have shown that the efficacy of ICSs in the prevention of exacerbations is higher in patients with high concentrations of blood eosinophils, but very limited in patients with blood eosinophil levels below 100 cells·μL–1 [2, 3]. Despite these indications, studies in different countries have demonstrated excessive and inadequate use of ICS in patients with mild or moderate COPD who are at low risk of exacerbations [4–6].

The development of inhaled forms of corticosteroids for respiratory diseases, initially asthma and later COPD, represented a great advance, because they opened up the possibility of adequately treating these diseases with lower doses of corticosteroids and with significant reductions in systemic exposure to the drug. However, there is some systemic absorption of ICSs [7], and due to the prolonged life expectancy of patients with COPD, patients can be exposed to the drug for decades, with possible risks of long-term corticosteroid-related side-effects. This is particularly important in COPD, because the population affected is usually older individuals with frequent comorbidities, such as type 2 diabetes mellitus and mycobacterial infections, among others, which may be susceptible to being aggravated by corticosteroids [8].

The large randomised clinical trials (RCTs) conducted at the beginning of the century revealed an increased risk of nonfatal pneumonia associated with the use of ICSs in COPD [9]. In addition, several studies observed a relationship between ICSs and local disorders such as oral candidiasis and dysphonia [10]; however, other less frequent side-effects may require larger populations exposed for longer periods of time to be identified.

We undertook the following analysis with the objectives of identifying and describing studies reporting the risks of adverse events associated with long-term use of ICSs in adult patients with COPD and estimating these risks.

Methods

Design and selection criteria

We conducted a systematic review with a broad focus, including a diversity of types of study designs and safety outcomes. Studies were included that met the following criteria for study design, population, intervention and outcomes: 1) RCTs, observational controlled studies (prospective or retrospective cohort studies, nested case–control studies (NCCs) and single cohort studies (if the sample was >500 participants); 2) adult patients diagnosed with COPD (if the study included a mixed population, specific data for patients with COPD should be available); 3) studies reporting data on safety outcomes in patients exposed to long-term use (defined as at least a 1-year period of continuous treatment) of ICSs alone or in combination; 4) studies reporting the rate (or the odds for case–control studies) of at least one of the following safety outcome measures: pneumonia, mycobacterium infections (tuberculosis (TB) and nontuberculous mycobacteria (NTM)), sepsis, osteoporosis, bone fractures, diabetes mellitus (new-onset, progression and/or switch from oral medication to insulin), glaucoma, cataract, hypertension, adrenal insufficiency, dysphonia and oral candidiasis.

The study was registered in Prospero (CRD42020168023) in April 2020.

Search strategy and study selection

For the electronic search, we designed a specific algorithm for MEDLINE and EMBASE (supplementary table S1). In addition, we performed a search for other reviews, either systematic or narrative, on the safety of ICSs and manually reviewed all the references included. The Covidence® software was used to manage the bibliography retrieved from the search across all the review process. Three authors (A. Auladell-Rispau, J. Mohammed and G. Urrútia), working in pairs, screened the search results based on the title and abstract independently. A full-text copy of each eligible reference was retrieved and the same researchers independently confirmed eligibility based on the inclusion criteria. Disagreements were discussed and solved by consensus.

Data extraction

The same authors extracted all relevant data on the main characteristics (design and methods, study population and intervention) and results of the selected studies.

Data analysis

Since the review includes several study designs that cannot be combined in a meta-analysis, the results are presented separately for each type of study design. Whenever possible, a meta-analysis was performed separately for RCTs and cohort studies, providing that these studies reported a measure of comparative effects such as hazard ratios (HR) or risk ratios (RR). Data are displayed using forest plots. We examined between-study heterogeneity using the I2 statistic. The quality of the clinical trials included in the meta-analyses was evaluated with the Cochrane risk of bias assessment tool [11]. When studies performed comparisons using ICSs in both study groups, results (rates) were reported narratively. Likewise, in NCC studies, in which the measure of association was the odds ratio (OR), the results are presented narratively.

Results

Our search in MEDLINE through PubMed yielded a total of 2711 bibliographic references, and the search in EMBASE provided 4287 references; both searches included references published up to 20 October 2020. An additional search was performed to identify other reviews related to this topic and included a total of 240 references. The search results, as well as the decisions made during the eligibility process, are shown in a PRISMA flowchart (supplementary figure S1). A total of 90 references from 83 studies were included in the review, corresponding to 26 RCTs [9, 12–43], 33 cohort studies [44–76] and 24 NCC studies [77–100]. A complete description of these studies is provided in supplementary table S2. Safety outcomes have been grouped into four main categories according to the nature of the events: infectious, metabolic, local and other.

Infectious adverse events

Pneumonia

In total, 47 studies reported this outcome (19 RCTs, 20 cohort studies and eight NCC studies). The pooled analysis of 19 RCTs with 66 485 participants showed that exposure to ICSs for ≥1 year increased the risk of pneumonia by 41% (RR 1.41, 95% CI 1.23–1.61; p<0.00001; I2=55%) [9, 12–14, 16, 19, 22, 23, 25, 26, 29, 30, 33–39] (figure 1). An interaction was found between the risk of pneumonia and the type of ICS used, with the highest risk being associated with fluticasone (10 studies with 45 870 participants) [9, 12–14, 16, 23, 25, 26, 30, 39]. A similar trend was observed with beclometasone (two studies with 4221 participants) [33, 38] and mometasone (one study with 911 participants) [22], but the low number of available studies limited the statistical power of the analysis and, therefore, resulted in a low-precision estimate. Conversely, exposure to budesonide (six studies with 13 479 participants) [19, 29, 34–37] was not associated with an increased risk of pneumonia, although a high heterogeneity was observed due to a recent large study which observed an increased risk [34]. Of the 21 cohort studies that reported this outcome, 16 described the effects in terms of HR and could be meta-analysed [46, 47, 49, 50, 53, 54, 57–59, 61, 66–69, 73, 74]. Exposure to ICSs for ≥1 year increased the risk of pneumonia by 26% (HR 1.26, 95% CI 1.14–1.38, p=0.0001; I2=93%) (supplementary figure S2).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Pooled risk ratios for pneumonia (Mantel-Haenszel, random-effects model). ICS: inhaled corticosteroid.

The remaining studies which were not suitable for the meta-analysis are summarised in table 1. Of these, only one study compared ICS use with no ICS use [71], while the remaining studies used ICSs in both study arms and, therefore, only provided descriptive frequency data. Incidence rates were highly variable among studies, and the risk of pneumonia in patients receiving fluticasone seemed to be higher than in patients receiving budesonide [52, 72], although one other study did not show this association [55]. According to one study (that was included in the meta-analysis), the risk of pneumonia was associated with higher doses of ICSs and the effects of ICSs were only significant in patients with forced expiratory volume in 1 s (FEV1) ≥50% [53].

View this table:
  • View inline
  • View popup
TABLE 1

Outcomes from cohort studies (not suitable for meta-analysis)

The results of eight NCC studies are summarised in table 2 [80, 81, 88, 92, 96, 97, 99, 100]. Overall, they confirm the association between ICS exposure and the risk of pneumonia. Higher doses of ICSs, current use of ICSs and exposure to fluticasone were also found to be associated with a higher risk of pneumonia.

View this table:
  • View inline
  • View popup
TABLE 2

Outcomes from nested case–control studies

TB and NTM

Nine studies reported this outcome: five cohort studies [56, 65, 71, 75, 76] and four NCC studies [77–79, 90]. None of these studies were suitable for a meta-analysis. Overall, the cohort studies found that the use of ICSs was associated with the risk of developing TB, especially for patients receiving high ICS doses and with a history of previous pulmonary TB [56, 65, 75]. Only one study did not find this association [71]. According to one study, long-term treatment with budesonide was associated with rates of TB similar to those with fluticasone [76]. Two NCC studies observed an association between ICS exposure and pulmonary TB [78, 90] and two others associated ICSs with NTM [77, 79] (tables 1 and 2).

Sepsis

Only one cohort [70] and one NCC study [82] related to the development of sepsis were identified. The cohort study compared the effect of budesonide and fluticasone on the risk of sepsis in patients with COPD and found incidence rates of sepsis of 4.99 and 5.74 per 100 person-years, respectively. Fluticasone was associated with a higher risk of sepsis (adjusted HR (aHR) 1.15, 95% CI 1.07–1.24) and septic shock (aHR 1.14, 95% CI 1.01–1.29) compared with budesonide [70].

The NCC study included 163 514 patients treated for COPD, 1704 of whom were hospitalised or died with sepsis during follow-up (incidence rate 1.94 per 1000 per year). The risk of sepsis was not increased with ICS, even at high doses, while the risk was increased with oral corticosteroids [82].

Metabolic adverse events

Osteoporosis

In total, 12 studies reported this outcome (eight RCTs, two cohort studies and one case–control study). The reporting methods for bone mineral density (BMD) data in the RCTs precluded pooling results in a meta-analysis [9, 21, 28, 29, 31, 32, 35, 42]. In one study, BMDs of the lumbar spine (p=0.007) and the femoral neck (p<0.001) were significantly lower in the ICS group (triamcinolone) versus placebo after 3 years [42]. Another study showed small but statistically significant differences in changes from baseline for budesonide 320 μg compared with all other treatments for total lumbar spine BMD (p≤0.037) and for budesonide 320 μg versus formoterol for total hip BMD (p=0.012) [35]. However, the remaining six RCTs did not find such an effect [9, 21, 28, 29, 31, 32].

In addition, two cohort studies reported a significant BMD decline with ICS use [60], and an evident dose–response relationship with increased risk of osteoporosis at mean ICS exposures of 500 μg·day–1 or greater [62]. Finally, one NCC found that long-term use of ICSs was associated with osteoporosis in multivariate regression analysis (HR 0.70, 95% CI 0.59–0.83; p<0.0001) [91].

Fractures

In total, 19 studies reported this outcome: nine RCTs, five cohort studies and five NCC studies. The pooled analysis of 10 RCTs with 41 342 participants did not observe a higher risk of fracture with exposure to ICSs (RR 1.10, 95% CI 0.97–1.25; p=0.13; I2=0%) [9, 14, 16, 18, 24, 25, 27, 31, 34, 43] (figure 2). No differences were observed depending on the type of ICS used; however, this analysis is not very informative since all but two studies used fluticasone [27, 34].

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Pooled risk ratios for fractures (Mantel-Haenszel, random-effects model). ICS: inhaled corticosteroid.

Five cohort studies reported this outcome [46, 49–51, 54]; of these, only three compared ICSs versus no ICSs and reported the effects in terms of HRs. These studies did not find an increased risk of fractures in patients exposed to ICSs for ≥1 year (HR 1.00, 95% CI 0.97–1.03, p=0.79; I2=0%) [49, 50, 54] (supplementary figure S3). Two additional cohort studies reported on fractures, but as they lacked a control group without ICS use, the results are presented in a descriptive way (rates) in table 1 [46, 51]. Four out of the five NCC studies showed an increased risk for fractures with ICS use [84, 89, 93, 95], with two showing an increasing risk with increased doses of ICSs [84, 95] and one found an increased risk only with fluticasone [93]. The remaining study only evaluated ICS exposure for up to 1 year and found no increased risk of nonvertebral fracture, but it could not evaluate long-term ICS use, very high ICS doses or vertebral fractures [87] (table 2).

Diabetes

The pooled analysis of four RCTs with 31 151 participants showed that long-term exposure to ICSs was not associated with an increased risk of diabetes (RR 1.10, 95% CI 0.96–1.26; p=0.15; I2=0%) [14, 16, 25, 34] (figure 3). However, four additional cohort studies found that exposure to ICSs for ≥1 year marginally increased the risk of new-onset diabetes (HR 1.06, 95% CI 1.00–1.13, p=0.06; I2=79%) [49, 54, 62, 64] (figure 4). This analysis included the most conservative estimate (risk associated with low-dose ICS) of one study [64], that showed a dose–response relationship with the HR ranging from 1.076–1.150 from low- to high-dose ICSs (all p<0.0001).

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Pooled risk ratios for diabetes (Mantel-Haenszel, random-effects model) in randomised clinical trials. Vestbo [14] and Dransfield [25] measured effects on glucose levels; Vestbo [16] and Rabe [34] measured hyperglycaemia/new-onset diabetes mellitus. ICS: inhaled corticosteroid.

FIGURE 4
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4

Pooled hazard ratios for diabetes (inverse variance method, random-effects model) in cohort studies. Data from Saeed [64] refer exclusively to patients treated with low-dose inhaled corticosteroids (ICS).

Among the five cohort studies, two found an association between ICSs and risk of diabetes onset [44, 63], one found an increased risk to progression to insulin treatment with high ICS doses [62] and another found an association between high ICS doses and increased risk of diabetes-related hospitalisations [45]. Only one study did not find an association between ICS use and diabetes [49] (table 1). Two NCCs also found a positive association between exposure to ICSs and an increased risk in diabetes-related outcomes, in particular with high doses of ICSs [83, 98] (table 2).

Local complications

Eye disorders

13 studies reported this outcome (nine RCTs, two cohort studies and three NCC studies). The pooled analysis of nine RCTs with 40 981 participants showed that exposure to ICSs was associated with a trend to a higher risk of an eye disorder, but the increase was not statistically significant (RR 1.08, 95% CI 0.93–1.25; p=0.32; I2=0%) [9, 14, 16, 18, 24, 25, 29, 34, 40] (supplementary figure S4). The results did not change when evaluating cataracts or other eye disorders separately (supplementary figure S5).

Two additional cohort studies assessed this outcome, with conflicting results. While one study [49] observed an increased risk of cataract development associated with cumulative ICS exposure (HR 1.43, 95% CI 1.11–1.84), another study [54] reporting on patients undergoing cataract surgery did not observe this association (HR 0.93, 95% CI 0.88–0.98). Only one of the three NCC studies found a significant association between ICS use and cataract development [86], but no association with glaucoma was described [85, 93, 96] (table 2).

Oral candidiasis

The pooled analysis of 16 RCTs with 33 725 participants showed that exposure to ICSs almost tripled the risk of oral candidiasis (RR 2.89, 95% CI 2.36–3.55; p<0.00001; I2=32%) [9, 12, 18–20, 22, 24, 26, 27, 33–35, 38–40, 43] (supplementary figure S6). The results were quite consistent across studies and also according to the ICS used.

Only one cohort study assessed this outcome [48]. The rate of oral candidiasis in patients exposed to ICSs was 5.5%, with a significant increased risk compared with non-ICS users. No significant difference was observed between patients exposed to budesonide and fluticasone. A pattern of increasing odds for oral candidiasis with increasing ICS dose was observed [48].

Dysphonia

The pooled analysis of nine RCTs with 22 841 participants showed that exposure to ICSs increased the risk of dysphonia by 277% (RR 3.77, 95% CI 2.81–5.05; p<0.00001; I2=0%) [9, 12, 13, 18, 22, 29, 34, 35, 38] (supplementary figure S7). The results were highly consistent across studies and also according to the ICS used.

Other adverse events

Hypertension

The pooled analysis of eight RCTs with 48 207 participants showed that exposure to ICSs was not significantly associated with an increased risk of hypertension overall (RR 1.05, 95% CI 0.89–1.24; p=0.57; I2=39%) [9, 14, 17, 22, 30, 33, 34, 36] (supplementary figure S8).

Adrenal suppression

Two RCTs assessed this outcome. One case of adrenal insufficiency in patients assigned to fluticasone (n=4135) was observed in one study [16]. The other trial found no evidence that long-term use of a moderate dose of inhaled triamcinolone suppresses either basal or stimulated adrenal function in older patients with COPD (n=221) [41].

Discussion

Treatment of respiratory diseases with ICSs has significantly reduced the risk of side-effects associated with the chronic use of oral corticosteroids; however, the use of ICSs is not free from possible complications. In this systematic review we observed a significantly increased risk of local side-effects, such as oral candidiasis and dysphonia; and an increased risk of some systemic effects such as respiratory infections (pneumonia and mycobacterial disease). Other systemic side-effects such as diabetes-related outcomes and bone fractures were only significantly associated with ICSs at high doses and with prolonged exposures in some studies, especially cohort and NCC studies. Finally, we could not find clear evidence of increased risk of sepsis, eye disorders, hypertension or adrenal suppression.

In this analysis we included not only RCTs, but also cohort and NCC studies, because most RCTs have a duration of 1 year, and this duration may not be long enough to investigate the risk associated with ICSs treatment. It should be taken into account that patients with COPD could be treated with ICSs for decades, and these patients are usually elderly with frequent comorbidities [8], making them more susceptible to the development of corticosteroid-related side-effects. The quality of the RCTs included in the meta-analyses was, in general, high. Only observational studies were included in the narrative review (with the exception of a few cohort studies) and these studies were not used to estimate the magnitude of the associations between ICSs and side-effects; therefore, no quality analysis was conducted. In general, the quality of observational studies is low (or at best moderate) because: 1) control of confounding variables is not adequate; 2) there is no blinding of the interventions to prevent measurement errors; and 3) they are often retrospective and collect information from registries of medical records from administrative databases. For these reasons, they have only been included in our review as complementary information. The descriptive data in supplementary table S2 provide complete details about the characteristics of these studies that will help the interested reader to interpret their results.

An increased susceptibility to infections is a recognised side-effect of the use of systemic corticosteroids. Among other properties, corticosteroids, including ICS, decrease the macrophage production of cytokines that is required for antibacterial immunity [101]. Our meta-analysis of data from 19 RCTs demonstrated a 41% increased risk of pneumonia with ICS, and this significant increase was also observed in cohort and NCC studies. The increased risk of pneumonia was well identified in the 3-year TORCH study with fluticasone propionate [9]. Since then, several studies and reviews have confirmed this association. In 2014, a Cochrane review concluded that the use of ICSs in COPD was associated with an increased risk of serious adverse pneumonia events, but it did not significantly affect mortality [102]. The authors could not find significant differences in risk between fluticasone propionate and budesonide. In contrast, we observed a reduced risk of pneumonia with budesonide compared with fluticasone, as suggested by other authors [52]. A recent systematic review of evidence from direct-comparison studies showed a significantly increased risk of 13.5% and 14.4% for pneumonia and severe pneumonia, respectively, among fluticasone compared with budesonide users [103].

The risk associated with the use of ICSs may be more relevant in patients with other risk factors for pneumonia. In two replicate, 1-year studies, the risk factors associated with at least a two-fold increase in the risk of pneumonia with fluticasone furoate treatment were being a current smoker, having prior pneumonia, a body mass index <25 kg·m−2, and severe airflow limitation [104]. Another factor to consider is the blood eosinophil count, since an increased risk of pneumonia has been observed when ICSs are prescribed to COPD patients with low blood eosinophil counts [105], and particularly if they have chronic bronchial infection or associated bronchiectasis [106].

The immunosuppressive effect of ICSs has been related to an increased risk of TB and nontuberculous mycobacteria pulmonary disease (NTM-PD); however, this effect has not been observed in RCTs due to the low incidence of cases of mycobacterial disease. A recent study observed an incidence rate of TB ranging from 0.15 to 0.17 per 100 person-years in fluticasone or budesonide users, respectively [75], which is approximately 100 times lower than the incidence of pneumonia in ICS users with COPD [52, 72]. Therefore, the impact of ICSs on pulmonary mycobacterial diseases should be explored in large observational studies. The majority of cohort and NCC studies indicated a significant increase in the risk of TB and NTM-PD associated with the use of higher ICS doses, without a clear difference between fluticasone and budesonide [56, 65, 75–78, 90, 92]. Interestingly, one of the most important risk factors for the development of TB in ICS users is a previous history of TB [56, 92]; therefore, the incidence of TB in patients with COPD treated with ICSs is very different in different geographic areas depending on the prevalence of TB in the area. Another interesting observation is that the use of oral corticosteroids is more strongly associated with the development of TB, and consequently, the increase in risk of TB associated with the use of ICSs is not observed in patients using oral corticosteroids simultaneously [76, 78].

The number of studies dedicated to the risk of NTM-PD is very limited, but they consistently show an increased risk with the use of ICS. Andréjak et al. [77] observed a significantly increased risk of NTM-PD in patients with COPD compared with controls, which was significantly higher with the current use of ICS, with higher doses of ICSs and with an increased number of previous hospital admissions. The adjusted OR for NTM-PD for COPD patients with current ICS use versus controls was 29.1 (95% CI 13.3–63.8).

In a large RCT, the use of triamcinolone was associated with a significant reduction of BMD [42], which was not observed in shorter, 1-year RCTs. Additionally, cohort studies show a relationship of ICS use with significant BMD decline and a dose–response relationship, with a significant effect at ICS doses of 500 μg·day–1 or greater [46, 51]. It is unclear whether and how these effects translate to fractures. The NCC studies showed a similar effect of ICSs in terms of an increase in risk of fractures with a dose–response relationship and only significant at high doses [84, 87, 89, 93, 95]. However, results from RCTs and cohort studies did not show a significant risk of fractures associated with ICS use. The lack of association observed in RCTs may be due to the shorter duration of observation and the selection of participants of a younger age and with fewer comorbidities. From the evaluation of the results, it appears that the risk of fractures is only significant when ICSs are used at high doses during prolonged periods of time and in particular in patients with other risk factors. One of the largest studies [84] found a 10% increased risk of fractures with the use of fluticasone at doses ≥1000 μg·day–1 for >4 years and an 11% increased risk with budesonide at doses ≥1600 μg·day–1 for >4 years. However, there are some uncertainties about this modest but significant increase in the risk of fractures. In fact, in a recent narrative review of the evidence, Caramori et al. [107] concluded that the exact relationship between long-term ICS use and bone fracture incidence in patients with COPD remains unclear, primarily due to the lack of information about baseline BMD and other risk factors for fractures such as smoking or physical activity as well as a lack of a standardised definition of fractures.

Systemic corticosteroids are known to increase the risk of diabetes, but the risk associated with ICSs is less clear. This is particularly important, because in most studies diabetes appears as one of the most frequent comorbidities in patients with COPD [8]. The meta-analysis of RCTs did not show a significant effect of ICSs on the risk of diabetes; however, the cohort and the NCC studies consistently showed an increased risk of diabetes-related outcomes, in particular when high doses of ICSs are used. A large study in Canada showed a 34% increase in the rate of diabetes and another 34% increase in the risk of diabetes progression, with these risks increasing to 64% and 54%, respectively, with the use of high doses of fluticasone of ≥1000 μg·day–1 [98].

We could not conclusively demonstrate an increased risk of eye disorders associated with ICS use in COPD. The pooled analysis of data from eight RCTs did not show a significant effect of ICSs on different eye problems. No evidence of an increased risk of glaucoma was observed in the cohort and NCC studies either; however, results for the associated risk of cataracts were more conflicting. One cohort and one NCC study found a significantly increased risk of cataracts associated with the cumulative ICS exposure [49, 85], while two other studies did not find any significant associations [54, 93].

In contrast to eye disorders, the results observed with other local side-effects such as oral candidiasis and dysphonia were much clearer. The use of ICSs was associated with an almost three-fold higher risk of oral candidiasis and almost 3.5-fold higher risk of dysphonia compared with non-users, without significant differences between different drugs. The high frequency of these disorders has been well documented in RCTs and also in observational studies and, although not severe, may result in discontinuation of treatment in some cases.

Since the long-term use of systemic corticosteroids may increase the risk of hypertension and adrenal suppression, we also wanted to investigate the evidence of a possible increase in the risk of these complications with the use of ICS. The pooled analysis of eight RCTs did not observe an increased risk of hypertension, and one RCT found only one case of adrenal insufficiency among >4000 patients treated with fluticasone [16]; consequently, no reliable conclusions could be drawn about the risk of adrenal suppression associated with the use of ICS.

Our study has attempted to provide a comprehensive overview of the risks associated with the use of ICSs in patients with COPD. However, it has the limitation that our search was restricted to studies on patients with COPD, and therefore, we may have missed some information from studies that analysed the adverse effects of ICSs in respiratory patients in general, without a clear identification of those with COPD.

In conclusion, we observed that the use of ICSs in patients with COPD is associated with an increased risk of several side-effects. The highest risk corresponded to local disorders, such as oral candidiasis and dysphonia, followed by infectious complications such as pneumonia and mycobacterial diseases, and diabetes-related outcomes, although with lower frequency. The risks of osteoporosis, bone fractures and eye disorders are less clear. For most of these complications a dose–response relationship was observed, indicating that lower doses of ICS should be used in patients with COPD whenever possible. This information should help clinicians to make informed decisions about the prescription of ICSs in patients with COPD.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary table 1 ERR-0075-2021_Table_S1

Supplementary table 2 ERR-0075-2021_Table_S2

Supplementary figure 1 ERR-0075-2021_Figure_S1

Supplementary figures 2-8 ERR-0075-2021_Figure_S2

Footnotes

  • This article has supplementary material available from err.ersjournals.com

  • Provenance: Submitted article, peer reviewed.

  • This study is registered on www.crd.york.ac.uk/prospero with identifier CRD42020168023.

  • Conflict of interest: M. Miravitlles reports speakers fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Zambon, Sandoz, CSL Behring, Grifols and Novartis; consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Kamada, TEVA, Sanofi, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols, outside the submitted work.

  • Conflict of interest: A. Auladell-Rispau has nothing to disclose.

  • Conflict of interest: M. Monteagudo has nothing to disclose.

  • Conflict of interest: J.C. Vázquez-Niebla has nothing to disclose.

  • Conflict of interest: J. Mohammed reports a grant from the European Respiratory Society (ERS Fellowship in Guidelines Methodology), outside the submitted work.

  • Conflict of interest: A. Nuñez has nothing to disclose.

  • Conflict of interest: G. Urrútia has nothing to disclose.

  • Support statement: This study was funded by an unrestricted grant from Boehringer Ingelheim. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received January 12, 2021.
  • Accepted March 26, 2021.
  • Copyright ©The authors 2021
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Nici L,
    2. Mammen MJ,
    3. Charbek E, et al.
    Pharmacologic management of chronic obstructive pulmonary disease. an official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201: e56–e69. doi:10.1164/rccm.202003-0625ST
    OpenUrlPubMed
  2. ↵
    1. Pascoe S,
    2. Barnes N,
    3. Brusselle G, et al.
    Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med 2019; 7: 745–756. doi:10.1016/S2213-2600(19)30190-0
    OpenUrl
  3. ↵
    1. Singh D,
    2. Bafadhel M,
    3. Brightling CE, et al.
    Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020; 202: 660–671. doi:10.1164/rccm.201912-2384PP
    OpenUrl
  4. ↵
    1. Barrecheguren M,
    2. Monteagudo M,
    3. Ferrer J, et al.
    Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med 2016; 111: 47–53. doi:10.1016/j.rmed.2015.12.004
    OpenUrl
    1. Koblizek V,
    2. Milenkovic B,
    3. Barczyk A, et al.
    Phenotypes of COPD patients with smoking history in central and Eastern Europe – the POPE Study. Eur Respir J 2017; 49: 1601446. doi:10.1183/13993003.01446-2016
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Casas A,
    2. Montes de OCA M,
    3. Menezes AM, et al.
    Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC Study. Int J Chron Obstruct Pulmon Dis 2018; 13: 1545–1556. doi:10.2147/COPD.S154097
    OpenUrl
  6. ↵
    1. Brutsche MH,
    2. Brutsche IC,
    3. Munawar M, et al.
    Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556–561. doi:10.1016/S0140-6736(00)02581-2
    OpenUrlCrossRefPubMed
  7. ↵
    1. Divo MJ,
    2. Casanova C,
    3. Marin JM, et al.
    COPD comorbidities network. Eur Respir J 2015; 46: 640–650. doi:10.1183/09031936.00171614
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Calverley PM,
    2. Anderson JA,
    3. Celli B, et al.
    Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789. doi:10.1056/NEJMoa063070
    OpenUrlCrossRefPubMed
  9. ↵
    1. Roland NJ,
    2. Bhalla RK,
    3. Earis J
    . The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004; 126: 213–219. doi:10.1378/chest.126.1.213
    OpenUrlCrossRefPubMed
  10. ↵
    1. Higgins JP,
    2. Altman DG,
    3. Gøtzsche PC, et al.
    The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928. doi:10.1136/bmj.d5928
    OpenUrlFREE Full Text
  11. ↵
    1. Aaron SD,
    2. Vandemheen KL,
    3. Fergusson D, et al.
    Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomised trial. Ann Intern Med 2007; 146: 545–555. doi:10.7326/0003-4819-146-8-200704170-00152
    OpenUrlCrossRefPubMed
  12. ↵
    1. Anzueto A,
    2. Ferguson GT,
    3. Feldman G, et al.
    Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009; 6: 320–329. doi:10.1080/15412550903140881
    OpenUrlCrossRef
  13. ↵
    1. Vestbo J,
    2. Leather D,
    3. Diar Bakerly N, et al.
    Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med 2016; 375: 1253–1260. doi:10.1056/NEJMoa1608033
    OpenUrlPubMed
    1. Bakerly ND,
    2. Woodcock A,
    3. Collier S, et al.
    Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups. Respir Med 2019; 147: 58–65. doi:10.1016/j.rmed.2018.12.016
    OpenUrl
  14. ↵
    1. Vestbo J,
    2. Anderson JA,
    3. Brook RD, et al.
    Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016; 387: 1817–1826. doi:10.1016/S0140-6736(16)30069-1
    OpenUrlPubMed
  15. ↵
    1. Brook RD,
    2. Anderson JA,
    3. Calverley PM, et al.
    Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart 2017; 103: 1536–1542. doi:10.1136/heartjnl-2016-310897
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Burge PS,
    2. Calverley PM,
    3. Jones PW, et al.
    Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–1303. doi:10.1136/bmj.320.7245.1297
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Calverley PM,
    2. Boonsawat W,
    3. Cseke Z, et al.
    Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912–919. doi:10.1183/09031936.03.00027003
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Calverley P,
    2. Pauwels R,
    3. Vestbo J, et al.
    Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456. doi:10.1016/S0140-6736(03)12459-2
    OpenUrlCrossRefPubMed
  19. ↵
    1. Ferguson GT,
    2. Calverley PMA,
    3. Anderson JA, et al.
    Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009; 136: 1456–1465. doi:10.1378/chest.08-3016
    OpenUrlCrossRefPubMed
  20. ↵
    1. Calverley PM,
    2. Rennard S,
    3. Nelson HS, et al.
    One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008; 9: 73. doi:10.1186/1465-9921-9-73
    OpenUrlCrossRefPubMed
  21. ↵
    1. Calverley PMA,
    2. Stockley RA,
    3. Seemungal TAR, et al.
    Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139: 505–512. doi:10.1378/chest.09-2992
    OpenUrlCrossRefPubMed
  22. ↵
    1. Wedzicha JA,
    2. Calverley PM,
    3. Seemungal TA, et al.
    The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19–26. doi:10.1164/rccm.200707-973OC
    OpenUrlCrossRefPubMed
  23. ↵
    1. Dransfield MT,
    2. Bourbeau J,
    3. Jones PW, et al.
    Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1: 210–223. doi:10.1016/S2213-2600(13)70040-7
    OpenUrl
  24. ↵
    1. Ferguson GT,
    2. Anzueto A,
    3. Fei R, et al.
    Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008; 102: 1099–1108. doi:10.1016/j.rmed.2008.04.019
    OpenUrlCrossRefPubMed
  25. ↵
    1. Pauwels RA,
    2. Löfdahl CG,
    3. Laitinen LA, et al.
    Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948–1953. doi:10.1056/NEJM199906243402503
    OpenUrlCrossRefPubMed
  26. ↵
    1. Johnell O,
    2. Pauwels R,
    3. Löfdahl CG, et al.
    Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002; 19: 1058–1063. doi:10.1183/09031936.02.00276602
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Kerwin EM,
    2. Ferguson GT,
    3. Mo M, et al.
    Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. Respir Res 2019; 20: 167. doi:10.1186/s12931-019-1126-7
    OpenUrl
  28. ↵
    1. Lipson DA,
    2. Barnhart F,
    3. Brealey N, et al.
    Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378: 1671–1680. doi:10.1056/NEJMoa1713901
    OpenUrlCrossRefPubMed
  29. ↵
    1. Maltais F,
    2. Schenkenberger I,
    3. Wielders PLML, et al.
    Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomised, controlled trial. Ther Adv Respir Dis 2020; 14: 1753466620965145.
    OpenUrl
  30. ↵
    1. Mathioudakis AG,
    2. Amanetopoulou SG,
    3. Gialmanidis IP, et al.
    Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial? Respirology 2013; 18: 147–153. doi:10.1111/j.1440-1843.2012.02265.x
    OpenUrlPubMed
  31. ↵
    1. Papi A,
    2. Vestbo J,
    3. Fabbri L, et al.
    Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391: 1076–1084. doi:10.1016/S0140-6736(18)30206-X
    OpenUrlCrossRefPubMed
  32. ↵
    1. Rabe KF,
    2. Martinez FJ,
    3. Ferguson GT, et al.
    Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020; 383: 35–48. doi:10.1056/NEJMoa1916046
    OpenUrl
  33. ↵
    1. Rennard SI,
    2. Tashkin DP,
    3. McElhattan J, et al.
    Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurised metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009; 69: 549–565. doi:10.2165/00003495-200969050-00004
    OpenUrlCrossRefPubMed
  34. ↵
    1. Sharafkhaneh A,
    2. Southard JG,
    3. Goldman M, et al.
    Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomised study. Respir Med 2012; 106: 257–268. doi:10.1016/j.rmed.2011.07.020
    OpenUrlCrossRefPubMed
  35. ↵
    1. Vestbo J,
    2. Sørensen T,
    3. Lange P, et al.
    Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–1823. doi:10.1016/S0140-6736(98)10019-3
    OpenUrlCrossRefPubMed
  36. ↵
    1. Vestbo J,
    2. Papi A,
    3. Corradi M, et al.
    Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017; 389: 1919–1929. doi:10.1016/S0140-6736(17)30188-5
    OpenUrlCrossRefPubMed
  37. ↵
    1. Wedzicha JA,
    2. Banerji D,
    3. Chapman KR, et al.
    Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016; 374: 2222–2234. doi:10.1056/NEJMoa1516385
    OpenUrlCrossRefPubMed
  38. ↵
    1. Wise R,
    2. Connett J,
    3. Weinmann G, et al.
    1. Lung Health Study Research Group
    , Wise R, Connett J, Weinmann G, et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902–1909. doi:10.1056/NEJM200012283432601
    OpenUrlCrossRefPubMed
  39. ↵
    1. Eichenhorn MS,
    2. Wise RA,
    3. Madhok TC, et al.
    Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest 2003; 124: 57–62. doi:10.1378/chest.124.1.57
    OpenUrlCrossRefPubMed
  40. ↵
    1. Scanlon PD,
    2. Connett JE,
    3. Wise RA, et al.
    Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004; 170: 1302–1309. doi:10.1164/rccm.200310-1349OC
    OpenUrlCrossRefPubMed
  41. ↵
    1. Wouters EF,
    2. Postma DS,
    3. Fokkens B, et al.
    Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480–487. doi:10.1136/thx.2004.034280
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Ajmera M,
    2. Shen C,
    3. Sambamoorthi U
    . Concomitant medication use and new-onset diabetes among medicaid beneficiaries with chronic obstructive pulmonary disease. Popul Health Manag 2017; 20: 224–232. doi:10.1089/pop.2016.0047
    OpenUrl
  43. ↵
    1. Caughey GE,
    2. Preiss AK,
    3. Vitry AI, et al.
    Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care 2013; 36: 3009–3014. doi:10.2337/dc12-2197
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Cho KH,
    2. Kim YS,
    3. Linton JA, et al.
    Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: a nationwide cohort study 2002–2013. Respir Med 2017; 130: 75–84. doi:10.1016/j.rmed.2017.07.012
    OpenUrl
  45. ↵
    1. Crim C,
    2. Calverley PM,
    3. Anderson JA, et al.
    Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641–647.doi:10.1183/09031936.00193908
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Dekhuijzen PNR,
    2. Batsiou M,
    3. Bjermer L, et al.
    Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. Respir Med 2016; 120: 54–63. doi:10.1016/j.rmed.2016.09.015
    OpenUrl
  47. ↵
    1. Flynn RW,
    2. MacDonald TM,
    3. Hapca A, et al.
    Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis. Respir Res 2014; 15: 141. doi:10.1186/s12931-014-0141-y
    OpenUrl
  48. ↵
    1. Gershon AS,
    2. Campitelli MA,
    3. Croxford R, et al.
    Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014; 312: 1114–1121. doi:10.1001/jama.2014.11432
    OpenUrlCrossRefPubMed
  49. ↵
    1. Gonnelli S,
    2. Caffarelli C,
    3. Maggi S, et al.
    Effect of inhaled glucocorticoids and β2 agonists on vertebral fracture risk in COPD patients: the EOLO study. Calcif Tissue Int 2010; 87: 137–143. doi:10.1007/s00223-010-9392-x
    OpenUrlCrossRefPubMed
  50. ↵
    1. Janson C,
    2. Larsson K,
    3. Lisspers KH, et al.
    Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ 2013; 346: f3306. doi:10.1136/bmj.f3306
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Janson C,
    2. Johansson G,
    3. Ställberg B, et al.
    Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study. Respir Res 2018; 19: 172. doi:10.1186/s12931-018-0868-y
    OpenUrl
  52. ↵
    1. Kendzerska T,
    2. Aaron SD,
    3. To T, et al.
    Effectiveness and safety of inhaled corticosteroids in older individuals with chronic obstructive pulmonary disease and/or asthma. A population study. Ann Am Thorac Soc 2019; 16: 1252–1262. doi:10.1513/AnnalsATS.201902-126OC
    OpenUrl
  53. ↵
    1. Kern DM,
    2. Davis J,
    3. Williams SA, et al.
    Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respir Res 2015; 16: 52. doi:10.1186/s12931-015-0210-x
    OpenUrl
  54. ↵
    1. Kim JH,
    2. Park JS,
    3. Kim KH, et al.
    Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest 2013; 143: 1018–1024. doi:10.1378/chest.12-1225
    OpenUrlCrossRefPubMed
  55. ↵
    1. Lee MC,
    2. Lee CH,
    3. Chien SC, et al.
    Inhaled corticosteroids increase the risk of pneumonia in patients with chronic obstructive pulmonary disease: a nationwide cohort study. Medicine (Baltimore) 2015; 94: e1723. doi:10.1097/MD.0000000000001723
    OpenUrl
    1. Lin SH,
    2. Ji BC,
    3. Shih YM, et al.
    Comorbid pulmonary disease and risk of community-acquired pneumonia in COPD patients. Int J Tuberc Lung Dis 2013; 17: 1638–1644. doi:10.5588/ijtld.13.0330
    OpenUrl
  56. ↵
    1. Lin SH,
    2. Perng DW,
    3. Chen CP, et al.
    Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease. Int J Chron Obstruct Pulmon Dis 2016; 11: 3051–3058. doi:10.2147/COPD.S115137
    OpenUrl
  57. ↵
    1. Liu SF,
    2. Kuo HC,
    3. Liu GH, et al.
    Inhaled corticosteroids can reduce osteoporosis in female patients with COPD. Int J Chron Obstruct Pulmon Dis 2016; 11: 1607–1614. doi:10.2147/COPD.S106054
    OpenUrl
  58. ↵
    1. Morros R,
    2. Vedia C,
    3. Giner-Soriano M, et al.
    Neumonías adquiridas en la comunidad en pacientes con enfermedad pulmonar obstructiva crónica tratados con corticoides inhalados u otros broncodilatadores. Estudio PNEUMOCORT [Community-acquired pneumonia in patients with chronic obstructive pulmonary disease treated with inhaled corticosteroids or other bronchodilators. Study PNEUMOCORT]. Aten Primaria 2019; 51: 333–340. doi:10.1016/j.aprim.2018.02.007
    OpenUrl
  59. ↵
    1. Price DB,
    2. Voorham J,
    3. Brusselle G, et al.
    Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. NPJ Prim Care Respir Med 2019; 29: 38. doi:10.1038/s41533-019-0150-x
    OpenUrl
  60. ↵
    1. Price DB,
    2. Russell R,
    3. Mares R, et al.
    Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. PLoS One 2016; 11: e0162903. doi:10.1371/journal.pone.0162903
    OpenUrlPubMed
  61. ↵
    1. Saeed MI,
    2. Eklöf J,
    3. Achir I, et al.
    Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease. Diabetes Obes Metab 2020; 22: 1348–1356. doi:10.1111/dom.14040
    OpenUrl
  62. ↵
    1. Shu CC,
    2. Wu HD,
    3. Yu MC, et al.
    Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine 2020; 89: 53–61. doi:10.1097/MD.0b013e3181cafcd3
    OpenUrl
  63. ↵
    1. Suissa S,
    2. Dell'Aniello S,
    3. Ernst P
    . Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med 2018; 6: 855–862. doi:10.1016/S2213-2600(18)30368-0
    OpenUrl
    1. Suissa S,
    2. Dell'Aniello S,
    3. Ernst P
    . Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest 2019; 155: 1158–1165. doi:10.1016/j.chest.2019.03.005
    OpenUrl
    1. Suissa S,
    2. Dell'Aniello S,
    3. Ernst P
    . Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice. Chest 2020; 157: 846–855. doi:10.1016/j.chest.2019.11.007
    OpenUrl
  64. ↵
    1. Tashkin DP,
    2. Miravitlles M,
    3. Celli BR, et al.
    Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial. Respir Res 2018; 19: 196. doi:10.1186/s12931-018-0874-0
    OpenUrl
  65. ↵
    1. Wang CY,
    2. Lin YS,
    3. Wang YH, et al.
    Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting beta2 agonists. Aging (Albany NY) 2019; 11: 6863–6871. doi:10.18632/aging.102217
    OpenUrl
  66. ↵
    1. Wu MF,
    2. Jian ZH,
    3. Huang JY, et al.
    Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD. BMC Cancer 2016; 16: 778. doi:10.1186/s12885-016-2838-4
    OpenUrl
  67. ↵
    1. Yang HH,
    2. Lai CC,
    3. Wang YH, et al.
    Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist. Int J Chron Obstruct Pulmon Dis 2017; 12: 2477–2485. doi:10.2147/COPD.S139035
    OpenUrl
  68. ↵
    1. Yawn BP,
    2. Li Y,
    3. Tian H, et al.
    Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 2013; 8: 295–304. doi:10.2147/COPD.S42366
    OpenUrlPubMed
  69. ↵
    1. Yeh JJ,
    2. Lin CL,
    3. Kao CH
    . Associations among chronic obstructive pulmonary disease with asthma, pneumonia, and corticosteroid use in the general population. PLoS One 2020; 15: e0229484.
    OpenUrl
  70. ↵
    1. Lee CH,
    2. Lee MC,
    3. Shu CC, et al.
    Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis 2013; 13: 194. doi:10.1186/1471-2334-13-194
    OpenUrlCrossRefPubMed
  71. ↵
    1. Huang TM,
    2. Kuo KC,
    3. Wang YH, et al.
    Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids. BMC Infect Dis 2020; 20: 706. doi:10.1186/s12879-020-05440-6
    OpenUrl
  72. ↵
    1. Andréjak C,
    2. Nielsen R,
    3. Thomsen VØ, et al.
    Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013; 68: 256–262. doi:10.1136/thoraxjnl-2012-201772
    OpenUrlAbstract/FREE Full Text
  73. ↵
    1. Brassard P,
    2. Suissa S,
    3. Kezouh A, et al.
    Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011; 183: 675–678. doi:10.1164/rccm.201007-1099OC
    OpenUrlCrossRefPubMed
  74. ↵
    1. Brode SK,
    2. Campitelli MA,
    3. Kwong JC, et al.
    The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J 2017; 50: 1700037. doi:10.1183/13993003.00037-2017
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Cascini S,
    2. Kirchmayer U,
    3. Belleudi V, et al.
    Inhaled corticosteroid use in chronic obstructive pulmonary disease and risk of pneumonia: a nested case-control population-based study in Lazio (Italy) – The OUTPUL Study. COPD 2017; 14: 311–317. doi:10.1080/15412555.2016.1254172
    OpenUrlPubMed
  76. ↵
    1. Ernst P,
    2. Gonzalez AV,
    3. Brassard P, et al.
    Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalisation for pneumonia. Am J Respir Crit Care Med 2007; 176: 162–166. doi:10.1164/rccm.200611-1630OC
    OpenUrlCrossRefPubMed
  77. ↵
    1. Ernst P,
    2. Coulombe J,
    3. Brassard P, et al.
    The risk of sepsis with inhaled and oral corticosteroids in patients with COPD. COPD 2017; 14: 137–142. doi:10.1080/15412555.2016.1238450
    OpenUrlPubMed
  78. ↵
    1. Gayle A,
    2. Dickinson S,
    3. Poole C, et al.
    Incidence of type II diabetes in chronic obstructive pulmonary disease: a nested case-control study. NPJ Prim Care Respir Med 2019; 29: 28. doi:10.1038/s41533-019-0138-6
    OpenUrl
  79. ↵
    1. Gonzalez AV,
    2. Coulombe J,
    3. Ernst P, et al.
    Long-term use of inhaled corticosteroids in COPD and the risk of fracture. Chest 2018; 153: 321–328. doi:10.1016/j.chest.2017.07.002
    OpenUrl
  80. ↵
    1. Gonzalez AV,
    2. Li G,
    3. Suissa S, et al.
    Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm Pharmacol Ther 2010; 23: 65–70. doi:10.1016/j.pupt.2009.10.014
    OpenUrlCrossRefPubMed
  81. ↵
    1. Jick SS,
    2. Vasilakis-Scaramozza C,
    3. Maier WC
    . The risk of cataract among users of inhaled steroids. Epidemiology 2001; 12: 229–234. doi:10.1097/00001648-200103000-00016
    OpenUrlCrossRefPubMed
  82. ↵
    1. Johannes CB,
    2. Schneider GA,
    3. Dube TJ, et al.
    The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest 2005; 127: 89–97. doi:10.1378/chest.127.1.89
    OpenUrlCrossRefPubMed
  83. ↵
    1. Joo MJ,
    2. Au DH,
    3. Fitzgibbon ML, et al.
    Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010; 104: 246–252. doi:10.1016/j.rmed.2009.10.002
    OpenUrlCrossRefPubMed
  84. ↵
    1. Lee TA,
    2. Weiss KB
    . Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 855–859. doi:10.1164/rccm.200307-926OC
    OpenUrlCrossRefPubMed
  85. ↵
    1. Lee CH,
    2. Kim K,
    3. Hyun MK, et al.
    Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013; 68: 1105–1113. doi:10.1136/thoraxjnl-2012-203175
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Lu PC,
    2. Yang YH,
    3. Guo SE, et al.
    Factors associated with osteoporosis in patients with chronic obstructive pulmonary disease – a nationwide retrospective study. Osteoporos Int 2017; 28: 359–367. doi:10.1007/s00198-016-3732-2
    OpenUrl
  87. ↵
    1. Mapel D,
    2. Schum M,
    3. Yood M, et al.
    Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim Care Respir J 2010; 19: 109–117. doi:10.4104/pcrj.2009.00072
    OpenUrlCrossRefPubMed
  88. ↵
    1. Miller DP,
    2. Watkins SE,
    3. Sampson T, et al.
    Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of nonvertebral fractures among patients with COPD in the UK General Practice Research Database. Phys Sportsmed 2010; 38: 19–27. doi:10.3810/psm.2010.12.1821
    OpenUrlPubMed
    1. Miller DP,
    2. Watkins SE,
    3. Sampson T, et al.
    Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Int J Chron Obstruct Pulmon Dis 2011; 6: 467–476.
    OpenUrlPubMed
  89. ↵
    1. Pujades-Rodríguez M,
    2. Smith CJ,
    3. Hubbard RB
    . Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease. QJM 2007; 100: 509–517. doi:10.1093/qjmed/hcm056
    OpenUrlCrossRefPubMed
  90. ↵
    1. Suissa S,
    2. Patenaude V,
    3. Lapi F, et al.
    Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029–1036. doi:10.1136/thoraxjnl-2012-202872
    OpenUrlAbstract/FREE Full Text
  91. ↵
    1. Suissa S,
    2. Coulombe J,
    3. Ernst P
    . Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest 2015; 148: 1177–1183. doi:10.1378/chest.15-0627
    OpenUrlCrossRefPubMed
  92. ↵
    1. Suissa S,
    2. Kezouh A,
    3. Ernst P
    . Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001–1006. doi:10.1016/j.amjmed.2010.06.019
    OpenUrlCrossRefPubMed
  93. ↵
    1. Thornton Snider J,
    2. Luna Y,
    3. Wong KS, et al.
    Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Curr Med Res Opin 2012; 28: 1959–1967. doi:10.1185/03007995.2012.743459
    OpenUrlCrossRefPubMed
  94. ↵
    1. Wang CY,
    2. Lai CC,
    3. Yang WC, et al.
    The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) study. Int J Chron Obstruct Pulmon Dis 2016; 11: 2775–2783. doi:10.2147/COPD.S116750
    OpenUrl
  95. ↵
    1. Sabroe I,
    2. Postma D,
    3. Heijink I, et al.
    The yin and the yang of immunosuppression with inhaled corticosteroids. Thorax 2013; 68: 1085–1087. doi:10.1136/thoraxjnl-2013-203773
    OpenUrlFREE Full Text
  96. ↵
    1. Kew KW,
    2. Seniukovich A
    . Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 10: CD010115.
    OpenUrl
  97. ↵
    1. Lodise TP,
    2. Li J,
    3. Gandhi HN, et al.
    Intraclass difference in pneumonia risk with fluticasone and budesonide in COPD: a systematic review of evidence from direct-comparison studies. Int J Chron Obstruct Pulmon Dis 2020; 15: 2889–2900. doi:10.2147/COPD.S269637
    OpenUrl
  98. ↵
    1. Crim C,
    2. Dransfield MT,
    3. Bourbeau J, et al.
    Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015; 12: 27–34. doi:10.1513/AnnalsATS.201409-413OC
    OpenUrlCrossRefPubMed
  99. ↵
    1. Pavord ID,
    2. Lettis S,
    3. Anzueto A, et al.
    Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med 2016; 4: 731–741. doi:10.1016/S2213-2600(16)30148-5
    OpenUrl
  100. ↵
    1. Martinez-Garcia MA,
    2. Faner R,
    3. Oscullo G, et al.
    Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease. A network analysis. Am J Respir Crit Care Med 2020; 201: 1078–1085. doi:10.1164/rccm.201908-1550OC
    OpenUrl
  101. ↵
    1. Caramori G,
    2. Ruggeri P,
    3. Arpinelli F, et al.
    Long-term use of inhaled glucocorticoids in patients with stable chronic obstructive pulmonary disease and risk of bone fractures: a narrative review of the literature. Int J Chron Obstruct Pulmon Dis 2019; 14: 1085–1097. doi:10.2147/COPD.S190215
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 30 Issue 160 Table of Contents
European Respiratory Review: 30 (160)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD
Marc Miravitlles, Ariadna Auladell-Rispau, Mònica Monteagudo, Juan Carlos Vázquez-Niebla, Jibril Mohammed, Alexa Nuñez, Gerard Urrútia
European Respiratory Review Jun 2021, 30 (160) 210075; DOI: 10.1183/16000617.0075-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD
Marc Miravitlles, Ariadna Auladell-Rispau, Mònica Monteagudo, Juan Carlos Vázquez-Niebla, Jibril Mohammed, Alexa Nuñez, Gerard Urrútia
European Respiratory Review Jun 2021, 30 (160) 210075; DOI: 10.1183/16000617.0075-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • The role of smoking on COVID-19 progression: a meta-analysis
  • PAP therapy for post-stroke sleep disordered breathing
  • Severe COVID-19 versus multisystem inflammatory syndrome
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society